Best Practices Forum: The role of icosapent ethyl for CV risk reduction
Details & Video
Program details and agenda: Select TABS on the left (computer) or SCROLL DOWN (phone)
Program Time: 60 minutes - This program is a recording of a live broadcast held on July 8, 2020
Accreditation-CME Credits: This program is not accredited. Physicians may earn self-learning credits through active steps. Instructions will be provided in the completion certificate. Target Audience: General practitioners and CV specialists
Target Audience: General practitioners and CV specialists
Perspectives from family practice, diabetology, and cardiology
Overview & Objectives
Best Practices Forum: The role of icosapent ethyl for CV risk reduction
Target Audience: General practitioners and CV specialists.
Perspectives from primary care,diabetology and cardiology.
Learning Objectives:
•To review the role of serum triglycerides as a risk marker vs. a risk factor
•To differentiate icosapent ethyl from standard fish oils
•To best apply the findings from the REDUCE-IT study to clinical practice
Faculty
Faculty
Milan Gupta
MD, FRCPC, FCCS
Associate Clinical Professor of Medicine,
McMaster University
Medical Director
Canadian Collaborative Research Network
View disclosures
David C. W. Lau
MD, PhD, FRCPC
Professor of Medicine,
Biochemistry & Molecular Biology
Julia McFarlane Diabetes Research Centre and
Libin Cardiovascular Institute of Alberta
University of Calgary Cumming School of Medicine
Richard Ward
MD, CCFP, FCFP
Clinical Associate Professor,
University of Calgary
Medical Director, Primary Care,
Alberta Health Services
Agenda
Agenda
| Program Chapter | Duration (Min:Sec) |
|---|---|
| Are serum triglycerides a risk factor? | |
| Do fish oils reduce CV risk? | |
| How does icosapent ethyl differ from fish oils? | |
| What are the main results of the REDUCE-IT study? | |
| What is the mechanism of benefit? | |
| How should we use icosapent ethyl in our practices? |
Sponsorship
This program was developed by the Canadian Collaborative Research Network and made possible through an educational grant from HLS Therapeutics Canada.
